The Community Guide

- gsearch

Search Results

Narrow Results:

2018 1
2017 2
2016 1

Journal Article 4

1 - 4 of 4 Results

Refine Results

Refine Results:

Oncologists’ influence on receipt of adjuvant chemotherapy: Does it matter whom you see for treatment of curable breast cancer?

CITE Title : Oncologists’ influence on receipt of adjuvant chemotherapy: Does it matter whom you see for treatment of curable breast cancer? Personal Author(s) : Katz, Steven J.;Hawley, Sarah T.;Bondarenko, Irina;Jagsi, Reshma;Ward, Kevin C.;Hofer, Timothy P.;Kurian, Allison W.; Published Date : Jul 08 2017 Source : Breast Cancer Res Treat. 165(3):751-756. URL : https://stacks.cdc.gov/view/cdc/59502 Katz, Steven J. et al. (2017). Oncologists’ influence on receipt of adjuvant chemotherapy: Does it matter whom you see for treatment of curable breast cancer?. 165(3). Katz, Steven J. et al. "Oncologists’ influence on receipt of adjuvant chemotherapy: Does it matter whom you see for treatment of curable breast cancer?" 165, no. 3 (2017) Katz, Steven J. et al. "Oncologists’ influence on receipt of adjuvant chemotherapy: Does it matter whom you see for treatment of curable breast cancer?" vol. 165, no. 3, 2017 Export RIS Citation Information.

:

Katz, Steven J. ;

Hawley, Sarah T.

Jul 08 2017 | Breast Cancer Res Treat. 165(3):751-756.

:

PurposeWe know little about whether it matters which oncologist a breast cancer patient sees with regard to receipt of chemotherapy. We examined oncol...
Surgeon influence on receipt of contralateral prophylactic mastectomy: Does it matter who you see for breast cancer surgery?

CITE Title : Surgeon influence on receipt of contralateral prophylactic mastectomy: Does it matter who you see for breast cancer surgery? Personal Author(s) : Katz, Steven J.;Hawley, Sarah T.;Hamilton, Ann S.;Ward, Kevin C.;Morrow, Monica;Jagsi, Reshma;Hofer, Timothy P.; Published Date : 1 2018 Source : JAMA Surg. 153(1):29-36 URL : https://stacks.cdc.gov/view/cdc/53383 Katz, Steven J. et al. (2018). Surgeon influence on receipt of contralateral prophylactic mastectomy: Does it matter who you see for breast cancer surgery?. 153(1). Katz, Steven J. et al. "Surgeon influence on receipt of contralateral prophylactic mastectomy: Does it matter who you see for breast cancer surgery?" 153, no. 1 (2018) Katz, Steven J. et al. "Surgeon influence on receipt of contralateral prophylactic mastectomy: Does it matter who you see for breast cancer surgery?" vol. 153, no. 1, 2018 Export RIS Citation Information.

:

Katz, Steven J. ;

Hawley, Sarah T.

1 2018 | JAMA Surg. 153(1):29-36

:

ImportanceRates of contralateral prophylactic mastectomy (CPM) have markedly increased but we know little about the influence of surgeons on variabili...
The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients

CITE Title : The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients Personal Author(s) : Li, Yun;Kurian, Allison W.;Bondarenko, Irina;Taylor, Jeremy M.G.;Jagsi, Reshma;Ward, Kevin C.;Hamilton, Ann S.;Katz, Steven J.;Hofer, Timothy P.; Published Date : Dec 23 2016 Source : Breast Cancer Res Treat. 161(3):587-595. URL : https://stacks.cdc.gov/view/cdc/43926 Li, Yun et al. (2016). The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. 161(3). Li, Yun et al. "The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients" 161, no. 3 (2016) Li, Yun et al. "The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients" vol. 161, no. 3, 2016 Export RIS Citation Information.

:

Li, Yun ;

Kurian, Allison W.

Dec 23 2016 | Breast Cancer Res Treat. 161(3):587-595.

:

PurposeTo quantify the influence of RS assay on changing chemotherapy plans in a general practice setting use using causal inference methods.MethodsWe...
Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer

CITE Title : Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer Personal Author(s) : Friese, Christopher R.;Harrison, Jordan M.;Janz, Nancy K.;Jagsi, Reshma;Morrow, Monica;Li, Yun;Hamilton, Ann S.;Ward, Kevin C.;Kurian, Allison W.;Katz, Steven J.;Hofer, Timothy P.; Published Date : Jan 24 2017 Source : Cancer. 123(11):1925-1934. URL : https://stacks.cdc.gov/view/cdc/45907 Friese, Christopher R. et al. (2017). Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer. 123(11). Friese, Christopher R. et al. "Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer" 123, no. 11 (2017) Friese, Christopher R. et al. "Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer" vol. 123, no. 11, 2017 Export RIS Citation Information.

:

Friese, Christopher R. ;

Harrison, Jordan M.

Jan 24 2017 | Cancer. 123(11):1925-1934.

:

BackgroundPatient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant data come from clinical trials and healthcar...